CAR-T in relapsed refractory high-grade glioma and glioblastoma – who, what, when and how?
Authors:
- Deevyashali ParekhDPDeevyashali Parekh
- Ansy H PatelAPAnsy H Patel
- Areeb KhanAKAreeb Khan
- Eloho OlojakpokeEOEloho Olojakpoke
- Ashay KarpeAKAshay Karpe
- Zoya PeelayZPZoya Peelay
- Vijay PatilVPVijay Patil
Open Access
- 30 September 2025
- journal article
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 19
Abstract
CAR-T in relapsed refractory high-grade glioma and glioblastoma – who, what, when and how? Deevyashali Parekh1, Ansy H Patel1, Areeb Khan1, Eloho OlojakpokKeywords
This publication has 30 references indexed in Scilit:
- B7-H3: An Attractive Target for Antibody-based ImmunotherapyClinical Cancer Research, 2020
- Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer TherapyFrontiers in Oncology, 2020
- Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor–transduced T Cells Targeting EGFRvIII in Patients With GlioblastomaJournal of Immunotherapy, 2019
- Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomasNature Medicine, 2018
- Lomustine and Bevacizumab in Progressive GlioblastomaNew England Journal of Medicine, 2017
- HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive GlioblastomaJAMA Oncology, 2017
- Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trialThe Lancet Oncology, 2014
- EphA3 Maintains Tumorigenicity and Is a Therapeutic Target in Glioblastoma MultiformeCancer Cell, 2013
- EphA2 as a Novel Molecular Marker and Target in Glioblastoma MultiformeMolecular Cancer Research, 2005
- Disialoganglioside GD2 in human neuroectodermal tumor cell lines and gliomasActa Neuropathologica, 1991